Surio’s leading cancer targeting technology, Active Tissue Targeting via Anchored ClicK Chemistry (最新版gateio官网) was originally developed in Prof. Cheng’s research group by Dr. Hua Wang and was later led by Dr. Kaimin Cai. The 最新版gateio官网 technology includes two steps (Scheme 1): 1) Cancer-specific labeling of azide (N3) on cancer cell surface by azido-sugar (Sugar-N3). N3-containing sugar is first delivered and metabolized specifically in cancer cell through the novel trigger-responsive design such that cancer cells surface would have enriched azide (N3) groups compared to the normal cell surface. 2) Targeted treatment of a dibenzocyclooctynes (DBCO)-containing therapeutic agent through highly specific DBCO-N3 Click reaction (specificity of Click reaction resembling antibody-antigen interaction). Since the cancer cell surface is modified with the artificial receptor (azide), the antibody-like DBCO can facilitate selectively accumulation of therapeutics in the tumors over normal tissues to achieve targeting enabled completely by small molecules through 最新版gateio官网.

Highlights of 最新版gateio官网:
1. 最新版gateio官网 inserts artificial antigens on cancer cell surface. It treats antibody untargetable cancers.
2. 最新版gateio官网 is a purely small molecule based targeting technology.
3. 10-100 times higher antigen copy per cell than endogenous antigens.
4. 最新版gateio官网 is a platform technology suitable for delivery of different therapeutics/diagnostic probes.

Copyright © 2012-2019 Surio Therapeutics Co., LTD. All rights reserved   ICP prepared ******** number

    Sina Weibo